Leisure Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Leisure Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$280K	Hold	28,000	–	–	0.09%	133
2026 Q1	$267K	Hold	28,000	–	–	0.09%	125
2025 Q4	$218K	Hold	28,000	–	–	0.07%	140
2025 Q3	$213K	Hold	28,000	–	–	0.07%	134
2025 Q2	$251K	Hold	28,000	–	–	0.09%	120
2025 Q1	$210K	Hold	28,000	–	–	0.09%	131
2024 Q4	$211K	Hold	28,000	–	–	0.08%	134
2024 Q3	$213K	Hold	28,000	–	–	0.09%	133
2024 Q2	$173K	Buy	+28,000	New	+$155K	0.08%	133

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Leisure Capital Management's BCRX Position: Q2 2026 in Review

Leisure Capital Management held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 28,000 shares worth $280K. The position accounts for 0.09% of the portfolio, ranked #133.

Leisure Capital Management first reported a position in BCRX in Q2 2024 and has held it in 9 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Leisure Capital Management held 28,000 shares of BioCryst Pharmaceuticals worth $280K as of Q2 2026.
Leisure Capital Management left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
BioCryst Pharmaceuticals made up 0.09% of Leisure Capital Management's portfolio in Q2 2026, its #133 holding.
Leisure Capital Management first reported a position in BioCryst Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Leisure Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.